ASZ1 and infection: While our results agree with previous work, in which the authors observed a delayed onset of putative eHEV particle infection following a prior treatment with anti-ORF3 antibodies [24], they remain difficult to translate to in vivo use of ORF3 as a vaccine candidate, since a protective effect relies on both the cellular and the humoral immune response.